Shares of ImmuPharma plc (LON:IMM – Get Free Report) traded up 29.3% on Thursday . The company traded as high as GBX 2.80 ($0.04) and last traded at GBX 2.78 ($0.04). 504,310 shares traded hands during trading, a decline of 95% from the average session volume of 10,802,349 shares. The stock had previously closed at GBX 2.15 ($0.03).
ImmuPharma Stock Performance
The firm’s 50 day moving average is GBX 3.46 and its 200 day moving average is GBX 2.52. The stock has a market cap of £11.37 million, a P/E ratio of -4.62 and a beta of 1.53.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
See Also
- Five stocks we like better than ImmuPharma
- Top Stocks Investing in 5G Technology
- Robinhood Strategies Could Be a Game-Changer for Young Investors
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Are These 3 Retail Stocks Oversold or Really in Trouble?
- Are Penny Stocks a Good Fit for Your Portfolio?
- IONQ & RGTI Join DARPA Quantum Initiative: High Stakes Are Ahead
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
